Quick Answer
Century Therapeutics, Inc. reported Operating Income Loss of -$17.27 million for the year ending 2025.
- Century Therapeutics, Inc. showed an increase of +87.5% in Operating Income Loss from 2024 to 2025.
- This data is from Century Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$15.52 million | Q3 2020: -$13.13 million | Q1 2021: -$18.06 million | Q2 2021: -$23.02 million | Q3 2021: -$25.83 million | Q1 2022: -$37.44 million | Q2 2022: -$31.35 million | Q3 2022: -$31.74 million | Q1 2023: -$32.08 million | Q2 2023: -$35.08 million | Q3 2023: -$35.63 million | Q1 2024: -$31.31 million | Q2 2024: -$34.76 million | Q3 2024: -$34.79 million | Q1 2025: $74.18 million | Q2 2025: -$34.66 million | Q3 2025: -$36.12 million.
- Over the full 6 years of available data (2020 to 2025), Century Therapeutics, Inc.'s Operating Income Loss has grown by 68.0%.
- Historical annual values: Fiscal year 2025: -$17.27 million | Fiscal year 2024: -$138.14 million | Fiscal year 2023: -$146.55 million | Fiscal year 2022: -$133.83 million | Fiscal year 2021: -$94.88 million | Fiscal year 2020: -$53.90 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: